Autism Advocates Accuse HHS of Spreading Misinformation

Autism advocates say the nation’s top health officials have pushed the US deeper into a misinformation crisis, turning public health into a fight over trust itself.

A recently released report accuses officials in the Trump administration, including Health and Human Services Secretary Robert F. Kennedy Jr., of fueling false or unsupported claims about autism and vaccines. According to the report, that campaign has weakened confidence in public health institutions and created what advocates describe as a crisis of public trust. The report urges Congress to hold oversight hearings and, in some cases, consider impeachment proceedings against officials it says helped spread harmful misinformation.

Advocates argue that misinformation from senior health officials does more than distort one issue — it erodes trust in the institutions people rely on when real health risks emerge.

The sharpest concerns center on the administration’s focus over the past year on autism, vaccines, and other disputed theories. Reports indicate officials have promoted or entertained claims linking autism to acetaminophen use during pregnancy, despite growing evidence showing no such connection. The report also points to the wholesale replacement of members on the federal autism committee with advisers described as having anti-vaccine views or pseudoscientific records, a move critics say reshaped federal guidance around ideology rather than evidence.

The dispute lands in a sensitive political and medical landscape, where vaccine confidence remains fragile and autism research already draws intense public attention. Critics argue that when senior officials amplify fringe ideas, they give those ideas a legitimacy they have not earned. That, in turn, can make it harder for families to sort evidence from speculation and harder for doctors, researchers, and agencies to communicate clearly.

What happens next will matter well beyond Washington. If Congress takes up the report’s demands, the fight could expand into a wider examination of how federal health leaders use their platforms and shape scientific panels. If it does not, advocates suggest the damage to public trust may deepen, leaving the country less prepared to respond when the next major health controversy arrives.